Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 332

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent

Open access
Foote, Kevin M., Nissink, J. Willem M., McGuire, Thomas, Turner, Paul, Guichard, Sylvie, Yates, James W. T., Lau, Alan, Blades, Kevin, Heathcote, Dan, Odedra, Rajesh, Wilkinson, Gary, Wilson, Zena, Wood, Christine M., Jewsbury, Philip J.·2018·Journal of Medicinal Chemistry

Abstract

The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a context where alternative pathways are less active is expected to aid clinical response by increasing replication stress. Here we describe the development of the clinical candidate 2 (AZD6738), a potent and selective sulfoximine morpholinopyrimidine ATR inhibitor with excellent preclinical physicochemical and pharmacokinetic (PK) characteristics. Compound 2 was developed improving aqueous solubility and eliminating CYP3A4 time-dependent inhibition starting from the earlier described inhibitor 1 (AZ20). The clinical candidate 2 has favorable human PK suitable for once or twice daily dosing and achieves biologically effective exposure at moderate doses. Compound 2 is currently being tested in multiple phase I/II trials as an anticancer agent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.8b01187

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Cited by

See all 332

Metadata

Authors
Foote, K. M., Nissink, J. W. M., McGuire, T., Turner, P., Guichard, S., Yates, J. W. T., Lau, A., Blades, K., Heathcote, D., Odedra, R., Wilkinson, G., Wilson, Z., Wood, C. M., & Jewsbury, P. J.
Venue
Journal of Medicinal Chemistry
Published
2018-10-22
Volume
61
Issue
22
Pages
9889-9907
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2897726163
Cited by
332
References
48
FWCI
8.24
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. https://app.cochat.ai/papers/10.1021/acs.jmedchem.8b01187
The paper
Foote, K. M., Nissink, J. W. M., McGuire, T., Turner, P., Guichard, S., Yates, J. W. T., Lau, A., Blades, K., Heathcote, D., Odedra, R., Wilkinson, G., Wilson, Z., Wood, C. M., & Jewsbury, P. J. (2018). Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.8b01187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.